Key Performance
More- Earnings Score: N/A
- Momentum Score: 86
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
Bright Minds Biosciences announced it will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company also granted 109,000 stock options to directors, officers, and consultants at an exercise price of US$83.40 per share, vesting over four years.
05/26/2026, 7:18 PM • GlobeNewswire
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
B Group, Inc. initiated a new position in Bright Minds Biosciences by purchasing 67,500 shares worth approximately $5.43 million in Q1 2026. The investment signals confidence in the company's epilepsy drug pipeline, particularly BMB-101. Bright Minds is a pre-clinical biotech firm with a well-funded balance sheet (C$309.7 million in cash) and no commercial revenue, representing a high-risk, high-reward opportunity for long-term investors.
05/21/2026, 5:31 PM • The Motley Fool
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
Bright Minds Biosciences (NASDAQ: DRUG) successfully closed a public offering of 1.945 million common shares at US$90 per share, raising US$175.05 million in gross proceeds. The company plans to use the net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, Prader-Willi Syndrome, and BMB-105, along with R&D and general corporate purposes.
01/09/2026, 11:56 AM • Benzinga
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
Bright Minds Biosciences priced an upsized public offering of 1,945,000 common shares at $90 per share for gross proceeds of $175.05 million. The company plans to use net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome, as well as phase 1 trials for BMB-105. The offering is expected to close on January 9, 2026.
01/07/2026, 9:33 PM • GlobeNewswire
Why Bright Minds Biosciences Stock Topped the Market on Monday
Bright Minds Biosciences strengthened its scientific advisory board with four experts in Prader-Willi Syndrome, launching a new investigational drug program targeting the rare genetic disorder. The company will evaluate existing and new treatment candidates, with initial Phase 1 studies focusing on safety and tolerability.
11/17/2025, 5:29 PM • The Motley Fool
Bright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences will present at the Guggenheim Healthcare Innovation Conference and Jefferies Global Healthcare Conference in November 2025, and has granted stock options to directors, officers, and consultants.
10/30/2025, 6:30 PM • GlobeNewswire
